Crescendo: BioNTech, Crescendo Biologics Ink 3-year Deal For Multi-target Discovery - Quick Facts
(RTTNews) - BioNTech SE (BNTX) and privately-held immuno-oncology company Crescendo Biologics Ltd. announced Monday that they have entered a multi...
Read full article »
Crescendo is an England-based clinical-stage immuno-oncology company that researches and develops T-cell human body therapeutics for the treatment of cancer.
Read more